Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Myelodysplastic Syndromes (MDS) represent a complex and heterogeneous group of hematopoietic stem cell disorders characterized by ineffective blood cell production and a distinct risk of transforming into acute leukemia. Often referred to as “bone marrow failure disorders,” MDS occurs when the microscopic factory inside the bones—the bone marrow—stops functioning correctly. Instead of producing healthy, mature blood cells that enter the circulation to perform vital functions, the marrow produces immature, defective cells known as “blasts” or dysplastic cells. These abnormal cells often die within the marrow before they ever reach the bloodstream, a process called intramedullary apoptosis. This results in fewer healthy blood cells in circulation, leading to the condition’s hallmark features of low blood counts, or cytopenias. At Liv Hospital, we approach MDS not merely as a form of anemia, but as a diverse spectrum of malignant conditions that requires precise biological characterization to manage effectively.
To understand MDS, one must first understand the normal process of blood formation, known as hematopoiesis.
In a healthy individual, all blood cells originate from a single type of master cell called the hematopoietic stem cell. These cells have the unique ability to self renew and to differentiate into various cell lines: red blood cells (for oxygen transport), white blood cells (for immune defense), and platelets (for clotting).
In MDS, a genetic mutation occurs in one of these stem cells. This mutated clone begins to dominate the marrow. However, unlike normal stem cells that mature in an orderly fashion, these clonal cells have a defect in their maturation process. They start to develop but get stuck at an immature stage. Under a microscope, these cells look abnormal or “dysplastic”—they may have strange shapes, abnormal sizes, or irregular nuclei.
Historically, MDS was often called “pre leukemia” or “smoldering leukemia.” While these terms are less commonly used today because they can be frightening, they describe an important biological reality.
MDS exists on a continuum. On one end, it behaves like a chronic anemia that stays stable for years. On the other end, it behaves like an aggressive cancer.
If the number of immature blast cells in the marrow continues to rise, the condition can transform into Acute Myeloid Leukemia (AML). By definition, if the blast count exceeds 20 percent of the cells in the bone marrow, the diagnosis shifts from MDS to AML. Preventing this transformation is a primary goal of treatment at Liv Hospital.
Because MDS is so varied, the World Health Organization (WHO) has created a classification system to group patients based on microscopic appearance and genetics.
In this type, only one type of blood cell (e.g., red blood cells) looks abnormal under the microscope, and blood counts are low in only one or two cell lines. This type typically has a better prognosis and slower progression.
Here, at least two types of blood cells (e.g., red cells and platelets) look abnormal. This is a more common form and may be associated with more severe cytopenias.
This is the most advanced form of MDS before leukemia. It is divided into Type 1 (5 to 9 percent blasts) and Type 2 (10 to 19 percent blasts). Patients with MDS EB have a significantly higher risk of progression to AML and require more aggressive management.
The behavior of MDS is largely dictated by changes in the DNA of the marrow cells.
About 50 percent of MDS patients have visible chromosomal changes. Common abnormalities include the deletion of part of chromosome 5 (del 5q), the loss of chromosome 7 (monosomy 7), or an extra chromosome 8 (trisomy 8).
Even in patients with normal chromosomes, modern sequencing often reveals mutations in specific genes such as SF3B1, TET2, ASXL1, or TP53. These mutations drive the disease and help doctors predict how the disease will behave. For example, the SF3B1 mutation is often associated with a specific subtype called MDS with ring sideroblasts, which generally has a milder course.
MDS is primarily a disease of aging, reflecting the accumulation of genetic damage over a lifetime.
The median age at diagnosis is approximately 70 to 75 years. It is relatively rare in people under 50 and very rare in children. As the global population ages, the incidence of MDS is rising.
The disease is slightly more common in men than in women, with the exception of the specific subtype associated with the 5q deletion, which is more common in women.
While most cases arise without a known cause (de novo MDS), a subset of patients develops “secondary” or “therapy related” MDS (t MDS). This occurs in people who have previously been treated with chemotherapy or radiation for other cancers. Therapy related MDS tends to be more aggressive and harder to treat due to complex genetic damage.
The central paradox of MDS is that the bone marrow is often hypercellular (packed with cells), yet the blood is cytopenic (empty of cells).
The marrow is working hard but producing “junk” cells. The body’s quality control mechanisms recognize these cells as defective and trigger programmed cell death (apoptosis) before they can leave the marrow.
Thrombocytopenia: Lack of platelets leads to bruising and bleeding risks.
Send us all your questions or requests, and our expert team will assist you.
Yes, MDS is considered a form of blood cancer because it involves the uncontrolled growth of abnormal cells, though some low risk forms behave more like a chronic illness.
No, but they are related. MDS involves less than 20% blast cells in the marrow, whereas leukemia has more than 20%. MDS can turn into leukemia over time.
Most cases are not inherited. They are caused by random mutations acquired during aging. Rare familial forms exist but are very uncommon.
Dysplastic means “abnormal looking.” In MDS, the blood cells look strange, misshapen, or irregular when viewed under a microscope.
Yes, but it is extremely rare in children. Pediatric MDS is biologically different from the adult form and is often linked to inherited genetic syndromes.
Your Comparison List (you must select at least 2 packages)
